None listed
Conditions
Interventions
Intervention1: Hydron Alkaline Ionized Water (HAIW): Dosage and Duration:
Subject will be asked to consume HAIW as and even required for 90 days
Control Intervention1: Packaged Drinking Water: Dosage
Sponsors
Hydron Alkaline Aqua Pvt. Ltd.
Eligibility
Inclusion criteria
Inclusion criteria: 1. Healthy, Male or Female subjects 2. Subjects who are ready to provide written informed consent and who are ready to willingly participate and follow the protocol requirements of the clinical study
Exclusion criteria
Exclusion criteria: 1. Pregnant and Lactating females 2. Uncontrolled cases of Diabetes and Hypertension 3. Subjects having any medical or surgical condition that would require immediate medical or surgical intervention at the time of screening 4. Subjects having immune compromised status like HIV, Hepatitis, Tuberculosis and Cancer etc. 5. Subjects taking steroid treatment and or any kind of immunosuppressive therapy 6. Subjects participating in any other clinical study or having participated in any other study 3 months prior to screening in the present study. 7. Subjects having allergy to alkaline water 8. Other conditions, which in the opinion of the investigators makes the patient unsuitable for enrolment or could interfere in adherence to of the study protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparative assessment of immunity fitness by measuring immunity parameters on self-reported scalesTimepoint: Screening/ Baseline Visit (Day 0), Day 30, Day 60, Day 90 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Comparative assessment of difference of absent days in office or workplace due to infections or allergies 2. Comparative assessment of number of participants for absent days in office or workplace due to infections or allergies 3. Comparative assessment of change in energy levels, physical fitness, strength and stamina 4. Comparative assessment of number of participants having change in energy levels, physical fitness, strength and stamina 5. Comparative assessment of change in quality of life as assessed using WHO QOL BREF 6. Comparative assessment of Physician s and Subject s Global evaluation for overall Change on CGI-I Scale 7. Assessment of incidence of adverse events, serious adverse events and vitals. Timepoint: Screening/ Baseline Visit (Day 0), Day 30, Day 60, Day 90 | — |
Countries
India
Contacts
Public ContactDr Sanjay Tamoli
Target Institute of Medical Education and Research Pvt. Ltd
Outcome results
None listed